Figure 6 | Scientific Reports

Figure 6

From: Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma

Figure 6

Dose responses of ACVR1 wild-type and G328V mutant DIPG cell viability to the treatment of SB525334, a selective inhibitor for TβRI over ACVR1. (a,b) Single agent study of TβRI inhibitors. **p < 0.01, ***p < 0.001, n = 4, unpaired t-test of highest dose vs. control. The genotypes for patient tumor derived DIPG cell lines are ACVR1 wild-type and histone H3.1K27M for SF8628 and ACVR1 G328V mutant and histone H3.3K27M for SU-DIPG-IV. DMEM (the default FBS-containing media for SF8628 used by manufacture and previous studies12) and TSM (a serum-free multi-growth factors-containing complex Tumor Stem Medium derived from previous studies on SU-DIPG-IV2,12) are different media culture conditions under examination (see methods).

Back to article page